We are live on ! Find out more
RXRX icon

Recursion Pharmaceuticals
RXRX

158 hedge funds and large institutions have $953M invested in Recursion Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 58 increasing their positions, 43 reducing their positions, and 26 closing their positions.

New
Increased
Maintained
Reduced
Closed

36% more call options, than puts

Call options by funds: $1.04M | Put options by funds: $765K

35% more repeat investments, than reductions

Existing positions increased: 58 | Existing positions reduced: 43

20% more funds holding in top 10

Funds holding in top 10: 5 → 6 (+1)

13% more capital invested

Capital invested by funds: $841M → $953M (+$111M)

0.32% more ownership

Funds ownership: 68.76% → 69.08% (+0.32%)

0% more funds holding

Funds holding: 158 → 158 (0)

0% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 26

Holders
158
Holders Change
–
Holders Change %
0%
% of All Funds
2.48%
Holding in Top 10
6
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+20%
% of All Funds
0.09%
New
26
Increased
58
Reduced
43
Closed
26
Calls
$1.04M
Puts
$765K
Net Calls
+$272K
Net Calls Change
+$22K

Top Buyers

1
KA
Kinnevik AB
Sweden
+$19.3M
2
YRHAM
Yong Rong (HK) Asset Management
Hong Kong
+$8.22M
3
AIM
ARK Investment Management
Florida
+$8.13M
4
BlackRock
BlackRock
New York
+$6.91M
5
LIM
Lingotto Investment Management
United Kingdom
+$5.42M

Top Sellers

1
LCM
Laurion Capital Management
New York
-$11.5M
2
Norges Bank
Norges Bank
Norway
-$9.51M
3
State Street
State Street
Massachusetts
-$4.72M
4
HMC
Harvard Management Company
Massachusetts
-$4.39M
5
Millennium Management
Millennium Management
New York
-$4.31M
Name Holding Trade Value Shares
Change 		Change in
Stake
AFG
151
Albion Financial Group
Utah
$897 -$28.4K -4,063 -97%
US Bancorp
152
US Bancorp
Minnesota
$859 +$805 +115 New
TAM
153
Tucker Asset Management
Colorado
$680 – – –
PA
154
Parallel Advisors
California
$486 +$455 +65 New
AF
155
Allworth Financial
California
$262 +$245 +35 New
WPWM
156
Western Pacific Wealth Management
Illinois
$149 – – –
FGAM
157
Financial Gravity Asset Management
Texas
$57 +$49 +7 New
Millennium Management
158
Millennium Management
New York
– -$4.31M -646,610 Closed
Marshall Wace
159
Marshall Wace
United Kingdom
– -$3.43M -514,137 Closed
CSS
160
Cubist Systematic Strategies
Connecticut
– -$2.71M -406,662 Closed
Connor, Clark & Lunn Investment Management (CC&L)
161
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
– -$1.52M -227,892 Closed
Two Sigma Investments
162
Two Sigma Investments
New York
– -$1.39M -208,143 Closed
TI
163
Trexquant Investment
Connecticut
– -$1.34M -200,366 Closed
Schroder Investment Management Group
164
Schroder Investment Management Group
United Kingdom
– -$879K -131,803 Closed
WHG
165
Westwood Holdings Group
Texas
– -$446K -66,872 Closed
DekaBank Deutsche Girozentrale
166
DekaBank Deutsche Girozentrale
Germany
– -$387K -60,000 Closed
Voloridge Investment Management
167
Voloridge Investment Management
Florida
– -$339K -50,834 Closed
XT
168
XTX Topco
Cayman Islands
– -$321K -48,138 Closed
Verition Fund Management
169
Verition Fund Management
Connecticut
– -$223K -33,400 Closed
OQS
170
Occudo Quantitative Strategies
Florida
– -$213K -31,977 Closed
ECM
171
ExodusPoint Capital Management
New York
– -$208K -31,137 Closed
BCM
172
Bayesian Capital Management
New York
– -$161K -24,095 Closed
Two Sigma Advisers
173
Two Sigma Advisers
New York
– -$103K -15,400 Closed
AC
174
AXQ Capital
New Jersey
– -$103K -15,374 Closed
BC
175
Bridgefront Capital
Texas
– -$97.4K -14,610 Closed
4 5 6
7
8

RXRX Hedge Fund Activity: Q2 2023 in Review

158 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Recursion Pharmaceuticals (RXRX) for Q2 2023, worth a combined $953M — up 13% from $841M a quarter earlier.

Fund positioning in RXRX was balanced in Q2 2023: 26 funds opened new positions, 26 closed out, 58 added to existing stakes and 43 trimmed.

The largest buyer was Kinnevik AB, adding an estimated $19.3M. The largest seller was Laurion Capital Management, cutting an estimated $11.5M.

  • 158 institutional investors held Recursion Pharmaceuticals (RXRX) as of Q2 2023, unchanged from Q1 2023.
  • Funds reported $953M of Recursion Pharmaceuticals stock for Q2 2023, up 13% quarter-over-quarter.
  • 26 funds opened new Recursion Pharmaceuticals positions in Q2 2023 and 26 closed out, a net change of 0 holders.
  • The largest Recursion Pharmaceuticals buyer in Q2 2023 was Kinnevik AB, an estimated $19.3M added.
  • The largest Recursion Pharmaceuticals seller in Q2 2023 was Laurion Capital Management, an estimated $11.5M sold.

Based on aggregated 13F filings for Q2 2023.